Neuphoria Therapeutics Set for Key Presentation on PTSD Treatment
Exciting Presentation by Neuphoria Therapeutics
BURLINGTON, Mass. — Neuphoria Therapeutics Inc. (Nasdaq: NEUP) has announced it will present at the esteemed American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. This exciting opportunity is set to showcase the valuable research being undertaken by the clinical-stage biotechnology company aimed at improving treatments for neuropsychiatric disorders.
About the Presentation
The presentation will focus on a vital aspect of Neuphoria's research, specifically a pharmacokinetic/pharmacodynamic analysis related to their drug candidate, BNC210. This analysis has critical implications not only for the planned Phase 3 study of post-traumatic stress disorder (PTSD) but also enhances our understanding of effective dose selection for these treatments.
Details of the Presentation
Neuphoria's presentation titled "Pharmacokinetic/Pharmacodynamic Analysis of the BNC210 Attune Phase 2b Dataset Enables Dose Selection for Planned Phase 3 PTSD Study" will be delivered by Spyros Papapetropoulos, M.D., Ph.D., who currently serves as the President and CEO of the company. The oral presentation is scheduled to take place during an individual research reports session, making it a focal point of discussion among professionals in the field.
When and Where to Attend
This significant event will occur on a Wednesday in May 2025, from 3:40 PM to 4:00 PM MST, in Fairmont Scottsdale Princess Salon Ballroom H. This setting is anticipated to foster dynamic discussions and networking opportunities for clinical professionals and investors alike.
About Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc., traded on Nasdaq under the ticker NEUP, is pioneering the development of therapies to address the multifaceted challenges of neuropsychiatric disorders. Their flagship drug candidate, BNC210, is being investigated as an innovative treatment option for conditions such as social anxiety disorder (SAD) and PTSD. Notably, BNC210 is distinguished by its role as a selective negative allosteric modulator of the ?7 nicotinic acetylcholine receptor, presenting a unique mechanism to provide relief from anxiety symptoms without the adverse effects of traditional treatments, such as sedation or addiction.
Innovative Research and Collaborations
Neuphoria is not just focused on BNC210; it also has a strategic partnership with Merck & Co., Inc., in which they are collaborating on research targeting cognitive deficits in Alzheimer's disease and other central nervous system conditions. This partnership underscores Neuphoria's commitment to advancing treatments that can significantly enhance the quality of life for patients afflicted with these complex disorders. In addition, the pipeline features next-generation programs targeting the ?7 nicotinic acetylcholine receptor and Kv3.1/3.2, both in stages of lead optimization development.
Future Perspectives on Neuropsychiatric Treatments
The upcoming presentation at the ASCP Annual Meeting marks a significant moment not just for Neuphoria but for the field of neuropsychiatry as a whole. As new research findings emerge, they promise to broaden our understanding and approach to treating conditions like PTSD, which affect countless individuals globally. The insights gleaned from examining BNC210’s efficacy and safety profile through rigorous clinical testing could become pivotal in creating guidelines for future therapies.
Connecting with Neuphoria
For anyone seeking additional insights or wishing to engage with Neuphoria, the company is reachable through various channels. Spyridon Papapetropoulos, the company's President and CEO, can be contacted directly at info@neuphoriatx.com. Investors keen on learning more can reach out to Kevin Gardner at kgardner@lifesciadvisors.com.
Frequently Asked Questions
What is the focus of Neuphoria's presentation at ASCP?
Neuphoria's presentation will analyze the BNC210 drug candidate's data, specifically for dose selection in planned Phase 3 PTSD studies.
Who will be presenting for Neuphoria?
Spyros Papapetropoulos, M.D., Ph.D., the President and CEO of Neuphoria Therapeutics, will deliver the presentation.
When is the presentation scheduled?
The presentation is scheduled for May 28, 2025, from 3:40 PM to 4:00 PM MST.
What is BNC210?
BNC210 is Neuphoria's lead drug candidate, designed to act as a selective negative allosteric modulator of the ?7 nicotinic acetylcholine receptor, targeting conditions like PTSD and social anxiety disorder.
How can I contact Neuphoria for further information?
General inquiries can be directed to Spyridon Papapetropoulos at info@neuphoriatx.com, or investors can reach Kevin Gardner at kgardner@lifesciadvisors.com.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
